Search

Axsome Therapeutics Inc

Închisă

SectorSănătate

144.04 -6.97

Rezumat

Modificarea prețului

24h

Curent

Minim

143.3

Maxim

154.83

Indicatori cheie

By Trading Economics

Venit

13M

-51M

Vânzări

27M

218M

EPS

-0.99

Marjă de profit

-23.498

Angajați

1,346

EBITDA

14M

-47M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+82.89% upside

Dividende

By Acuity

Următoarele câștiguri

2 nov. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-2.7B

8.2B

Deschiderea anterioară

151.01

Închiderea anterioară

144.04

Axsome Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

22 oct. 2026, 20:13 UTC

Axsome Therapeutics Inc shares are trading modestly lower in after-market hours, continuing a notably weak performance below its 20-day moving average.

21 oct. 2026, 23:11 UTC

Axsome Therapeutics Inc is trading higher in after-market hours, rebounding from a brief dip earlier in the session and reaching its highest point of the day.

20 oct. 2026, 23:51 UTC

Axsome Therapeutics Inc shares advanced sharply in after-market trading, rising from a low shortly after the market closed to a session high.

19 oct. 2026, 23:56 UTC

Axsome Therapeutics Inc shares are trading higher in after-market hours, having pulled back from an initial gain shortly after the market closed.

16 oct. 2026, 20:07 UTC

Axsome Therapeutics Inc shares are declining, consistent with broader market weakness, reaching their lowest point since Thursday's close amid a subdued trading environment.

15 oct. 2026, 20:07 UTC

Axsome Therapeutics Inc shares are declining, following volatility earlier in the session, and remain significantly below their 20-day moving average.

14 oct. 2026, 21:01 UTC

Axsome Therapeutics Inc shares are moving lower in after-market trading amid a broader market decline following increased inflation concerns and potential Fed interest rate hikes.

13 oct. 2026, 20:01 UTC

Axsome Therapeutics Inc shares fell sharply, breaking a recent trend of higher daily closes, contrasting with the upward momentum observed since Monday's close.

12 oct. 2026, 23:41 UTC

Axsome Therapeutics Inc shares advanced in after-market trading, showing gains after an initial dip, despite a broader decline over the past month.

9 oct. 2026, 19:35 UTC

Axsome Therapeutics Inc shares fell sharply during the current market session, reflecting a broader trend of lower daily closes over the past month.

8 oct. 2026, 23:01 UTC

Axsome Therapeutics Inc shares are modestly lower in after-market trading, continuing a downward trend since Thursday's close and remaining below its 20-day moving average.

7 oct. 2026, 20:08 UTC

News

Axsome Therapeutics Inc shares fell as the company announced its third-quarter financial results will be released on November 2, 2026, before market open.

6 oct. 2026, 22:35 UTC

Axsome Therapeutics Inc's shares are higher in after-market hours, despite a recent decline and nine consecutive sessions finishing lower.

5 oct. 2026, 19:35 UTC

Axsome Therapeutics Inc shares fell, continuing a downward trend with seven consecutive sessions of lower closes since the market opened.

2 oct. 2026, 20:12 UTC

Axsome Therapeutics Inc is trading modestly lower in after-market hours, continuing a trend with six consecutive sessions finishing lower.

1 oct. 2026, 20:07 UTC

Axsome Therapeutics Inc shares fell sharply, closing lower than Wednesday and remaining significantly below the 20-day moving average.

30 sept. 2026, 21:01 UTC

Axsome Therapeutics Inc's shares rose in after-market trading, supported by positive economic indicators, including stronger GDP growth and robust personal spending.

29 sept. 2026, 20:01 UTC

News

Shares of Axsome Therapeutics fell as Deutsche Bank maintained its Buy rating but lowered the price target to $267 amid reevaluated market conditions.

28 sept. 2026, 20:07 UTC

News

Axsome Therapeutics Inc shares fell amid a broader market downturn, despite presenting new Alzheimer’s agitation survey data at Psych Congress 2026.

25 sept. 2026, 20:07 UTC

News

Axsome Therapeutics shares fell after Morgan Stanley cut its price target to $247 from $251, contributing to a decline near the lower end of its one-month range.

24 sept. 2026, 20:07 UTC

Axsome Therapeutics Inc's shares advanced, recovering from four consecutive sessions of losses, though they remain below their 20-day moving average.

23 sept. 2026, 23:35 UTC

Axsome Therapeutics Inc is trading modestly higher in after-market hours following unusual activity, though it remains significantly below its 20-day moving average.

22 sept. 2026, 19:45 UTC

Axsome Therapeutics Inc shares fell sharply, trading below their 20-day moving average, marking three consecutive sessions of declines amid a weaker market trend.

21 sept. 2026, 20:12 UTC

Axsome Therapeutics Inc is trading modestly lower in after-market hours, remaining near the lower end of its one-month trading range and below its 20-day moving average.

18 sept. 2026, 19:46 UTC

Axsome Therapeutics Inc shares fell after reaching an early high, remaining below Thursday's close and stabilizing around the middle of its one-month trading range.

16 sept. 2026, 20:10 UTC

Macro Event

Axsome Therapeutics Inc is advancing amid broader market reactions to the Federal Reserve's 25 basis point interest rate hike, consolidating gains above its 20-day moving average.

15 sept. 2026, 21:01 UTC

Axsome Therapeutics Inc shares are lower in after-market hours, showing unusual volatility and trading below its 20-day moving average. No specific news was identified.

14 sept. 2026, 20:07 UTC

Social Media

Axsome Therapeutics shares are lower today, continuing a decline since Friday. Recent prescription data and a price target of $316 from Mizuho have not supported the stock.

12 sept. 2026, 00:01 UTC

Social Media

Axsome Therapeutics shares rise in after-market trading, supported by Mizuho's $316 price target and positive prescription data for Auvelity.

11 sept. 2026, 20:01 UTC

News
Social Media

Axsome Therapeutics shares rise following positive analyst commentary on Auvelity's launch and strong prescription growth, with unusually high trading volume today.

Comparație

Modificare preț

Axsome Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

82.89% sus

Prognoză pe 12 luni

Medie 285.875 USD  82.89%

Maxim 380 USD

Minim 247 USD

În baza a 17 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAxsome Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

17 ratings

16

Cumpărare

1

Păstrare

0

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
help-icon Live chat